Tumour lysis syndrome

Posted by Michael Jannicelli | Aug 22, 2024 | Uncategorized | 0 |

Nature Reviews Disease Primers, Published online: 22 August 2024; doi:10.1038/s41572-024-00542-w

Tumour lysis syndrome (TLS) is an oncological emergency characterized by extensive tumour cell breakdown, leading to the rapid release of intracellular contents into the systemic circulation. In this Primer, Howard and colleagues summarize the epidemiology, pathophysiology, diagnosis and management of TLS.

About The Author

Michael Jannicelli

Michael Jannicelli - "A PROVEN BUSINESS FIRESTARTER & BRANDING GENIUS" a true natural born Trendsetter. • Created over 100 products under 3 brands, sold in 30+ countries worldwide and influencing youth across the globe. • Featured in Forbes magazine +over 100 print publications, television talk shows, major motion pictures and national radio stations. • Co-founder and VP of Bliss beverage USA and President/co-founder of Socko International - fastest growing privately held beverage company in US (Forbes) with Hogan Energy & Raw Energy WWE. • Co-founder of Throwdown Industries (2003) - leading brand in multibillion dollar Impact/Action Sports Market (products designed for superior MN • Diagnosed with auto-immune diseases aged 13; using his experience to help others and promote a positive message while developing edgy products to benefit people with chronic illness.